Gene
AKT1
AKT1 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (86), Actionable biomarkers (7), and 8 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 more sections with rows · 1 section measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention AKT1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 108 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 9 of 8,738 | 0.10% | not measured | |
| 2025 | 10 of 8,875 | 0.11% | not measured | |
| 2024 | 11 of 8,597 | 0.13% | not measured | |
| 2023 | 6 of 8,275 | 0.07% | 284 of 11,460 | 2.48% |
| 2022 | 9 of 8,285 | 0.11% | 376 of 13,598 | 2.77% |
| 2021 | 11 of 8,692 | 0.13% | 486 of 15,045 | 3.23% |
| 2020 | 2 of 7,640 | 0.03% | 385 of 14,459 | 2.66% |
| 2019 | 4 of 7,300 | 0.05% | 355 of 12,159 | 2.92% |
| 2018 | 6 of 6,927 | 0.09% | 325 of 11,854 | 2.74% |
| 2017 | 8 of 6,558 | 0.12% | 348 of 11,595 | 3.00% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| FoundationOne CDx | AKT1 | Foundation Medicine, Inc. | Breast Cancer | 2023-11-16 |
Assay-provider ledger (86)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 9 | September 01, 2025 +1 undated |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 1 | September 01, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 7 | September 01, 2025 |
| OC Medicina de Precisão Oncoclínicas&Co (Oncoclínicas Medicina de Precisão, OCPM) | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 26, 2025 |
| PlexBio (Taiwan) | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 26, 2025 |
Showing 5 of 86 assay-provider companies.
Actionable biomarkers (7)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| AKT1 (Q79K,E17K) | Braf Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
| AKT1 (E17K) | Tensirolimus | response-associated | endometrial carcinoma | Cancer Genome Interpreter |
| AKT1 (E17K) | Pi3k Pathway Inhibitors | response-associated | head and neck squamous cell carcinoma | Cancer Genome Interpreter |
| AKT1 (H238Y) | EVEROLIMUS | response-associated | histiocytoma | Cancer Genome Interpreter |
| AKT1 (E17K) | Allosteric Akt Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Showing 5 of 7 actionable-biomarker assertions.
Trial mentions (134)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01605396 | Trial eligibility (AACT) |
| NCT05933395 | Trial eligibility (AACT) |
| NCT01485861 | Trial eligibility (AACT) |
| NCT05307705 | Trial eligibility (AACT) |
| NCT07255846 | Trial eligibility (AACT) |
Showing 5 of 134 trial mentions.
Target-disease associations (1,153)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XY partial gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| AKT2-related familial partial lipodystrophy | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Aarskog-Scott syndrome, X-linked | genetic, familial or congenital disease | Literature (Europe PMC) |
| Abdominal Aortic Aneurysm | cardiovascular disease | Literature (Europe PMC) |
Showing 5 of 1,153 associations.
Vendor sourcing (364)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV006583151.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The AKT1 c.176-5C>A variant (rs377076374) is reported in the literature in one individual affected with vascular anomalies (Mattassi 2018). This variant is f... | View ClinVar record SCV004562217.1 |
| Ability Pharmaceuticals SL | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Patients previously treated with an inhibitor of the Phosphoinositide 3-kinase/Protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway.... | View trial NCT03366480 |
| Ability Pharmaceuticals SL | Trial sponsor | Mentioned in trial textTrial free-text mention | Protein kinase B | View trial NCT03366480 |
| Adlai Nortye Biopharma Co., Ltd. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Have been discontinued treatment due to a Grade 3 or higher immune-related AE (irAE) from prior anti-PD-1or anti-PD-L1, or with an agent directed to an... | View trial NCT04975958 |
Showing 5 of 364 sourcing records.
Trial-cited literature (4,988)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. | Annals of oncology : official journal of the European Society for Medical Oncology | 2026 | 29 |
| The Inflammation-Energy Metabolism Axis: A Central Driver of Sarcopenia-Osteoporosis: A Narrative Review. | Calcified tissue international | 2026 | 10 |
| Current Status of Research on Losartan in Tumour Therapy. | Journal of cellular and molecular medicine | 2026 | 6 |
| Leveraging menstrual effluent (ME) to investigate vitamin D and human decidualization, a potential link with fertility. | The Journal of clinical endocrinology and metabolism | 2026 | 4 |
| Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. | Journal for immunotherapy of cancer | 2026 | 1 |
Showing 5 of 4,988 papers.
Protein variant mentions (47)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A67M | 1 | 2022 | PMID 35466524 |
| p.C60M | 1 | 2022 | PMID 35466524 |
| p.D44N | 1 | 2022 | PMID 35440569 |
| p.D61M | 1 | 2022 | PMID 35466524 |
| p.D9E | 3 | 2015 to 2020 | PMID 31924241, PMID 28368383, PMID 25730765 |
Showing 5 of 47 variants.
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.D44N | TCGA-UCEC | Not Reported; Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Corpus uteri; Uterus, NOS | 1 | 559 | 0.18% | 0.03% to 1.01% |
Literature-extracted relations (881)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Calcitriol | Chemical | negative_correlate |
Leveraging menstrual effluent (ME) to investigate vitamin D and human decidualization, a potential link with fertility. | 2026 |
| METFORMIN | Chemical | negative_correlate |
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial. | 2025 |
| FULVESTRANT | Chemical | associate |
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> Alterations. | 2024 |
| DEXMEDETOMIDINE | Chemical | associate |
Dexmedetomidine improves the circulatory dysfunction of the glymphatic system induced by sevoflurane through the PI3K/AKT/ΔFosB/AQP4 pathway in young mice. | 2024 |
| SEVOFLURANE | Chemical | associate |
Dexmedetomidine improves the circulatory dysfunction of the glymphatic system induced by sevoflurane through the PI3K/AKT/ΔFosB/AQP4 pathway in young mice. | 2024 |
Showing 5 of 881 relation assertions.
Organizations publishing (1,633)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 166 | 2004 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 160 | 2006 to 2025 |
| Government of the United States of America | Government | 155 | 2000 to 2026 |
| Harvard Medical School | Academic | 118 | 2002 to 2025 |
| Mass General Brigham | Hospital | 115 | 1995 to 2025 |
Showing 5 of 1,633 organizations.
Where AKT1 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
1,023 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects.